Search results
TG Therapeutics Announces Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the 2024...
Morningstar· 6 days agoTG Therapeutics, Inc. (NASDAQ: TGTX), today announced presentations highlighting study designs for post-marketing studies being undertaken for BRIUMVI® (ublituximab-xiiy) in patients with relapsing ...
BriaCell Presents Clinical Efficacy Data at ASCO 2024
Digital Journal· 3 days agoBriaCell doubles Progression-Free-Survival (PFS) and Clinical Benefit Rate vs historical results in the literatureBria-IMT™ PFS compares favorably to PFS of most recent treatment in 48% of Antibody-Drug ...
Small Business - Picayune Item | Picayune Item
The Picayune Item· 4 days ago- Clinically meaningful and statistically significant improvements across multiple angioedema measurements and barzolvolimab dose groups -- Sustained activity with rapid onset within 2 weeks -- Data further support barzolvolimab clinical benefit
TuHURA Biosciences and Kintara Therapeutics Announce Positive Results from Phase 1b Trial of...
Morningstar· 3 days agoTAMPA, FL and SAN DIEGO, CA / ACCESSWIRE / June 3, 2024 / TuHURA Biosciences, Inc. ("TuHURA"), a Phase 3 registration-stage immune-oncology company developing novel technologies to overcome ...
Virion Therapeutics Reports Positive First-in-human, First-in-class, Phase 1b Immunogenicity Data of...
Benzinga· 24 hours agoHighlights from the Data Presentation Initial immunogenicity (n=9) and ongoing safety data (n=13) presented in chronically HBV-infected patients following a single, low dose, prime-only intramuscular injection of
Small Business - Salisbury Post | Salisbury Post
The Salisbury Post· 6 days agoACI SANT'ANTONIO, Italy, May 31, 2024 /PRNewswire/ -- SIFI announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive ...
Small Business - Cordele Dispatch | Cordele Dispatch
Cordele Dispatch· 3 days agoLEXINGTON, Mass. and AMSTERDAM, June 03, 2024 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical ...
Small Business - The Brewton Standard | The Brewton Standard
The Brewton Standard· 6 days agoBlueprint Medicines Announces Data Presentations at EAACI and EHA Annual Meetings Highlighting Sustained Clinical Benefits of AYVAKIT®/AYVAKYT® (avapritinib) PR Newswire CAMBRIDGE, Mass., May ...
BriaCell Initiates Patient Enrollment in First-in-Human Study of Bria-OTS™ in Advanced Metastatic...
Digital Journal· 7 days agoPHILADELPHIA and VANCOUVER, British Columbia, May 30, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology ...
TuHURA reports breakthrough in cancer vaccine trial By Investing.com
Investing.com· 3 days agoTuHURA Biosciences, Inc., in collaboration with Kintara Therapeutics, Inc. (NASDAQ:KTRA), has...
